2-(4-piperidinylmethyl)-1H-benzimidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(4-piperidinylmethyl)-1H-benzimidazole
• 英文别名: 2-(Piperidin-4-ylmethyl)-1H-1,3-benzodiazole；2-(piperidin-4-ylmethyl)-1H-benzimidazole
• 化学式: C₁₃H₁₇N₃
• mdl: MFCD13875459
• 分子量: 215.298
• InChiKey: AJDJDMWYUXQCIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  对联苯磺酰氯 、 2-(4-piperidinylmethyl)-1H-benzimidazole 在 二乙基异丙基胺 作用下， 以 二氯甲烷 为溶剂， 生成 2-{[1-(biphenyl-4-ylsulfonyl)piperidin-4-yl]methyl}-1H-benzimidazole
  参考文献：
  名称：

  A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties

  摘要：

  We have been exploring the potential of 5-HT2B antagonists as a therapy for chronic heart failure. To assess the potential of this therapeutic approach, we sought compounds possessing the following attributes: (a) potent and selective antagonism of the 5-HT2B receptor, (b) low impact of serum proteins on potency, and (c) desirable pharmacokinetic properties. This Letter describes our investigation of a biphenyl benzimidazole class of compounds that resulted in 5-HT2B antagonists possessing the above attributes. Improving potency in a human serum albumin shift assay proved to be the most significant SAR discovery. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.126
• 作为产物：
  描述：

  2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1H-benzimidazole 生成 2-(4-piperidinylmethyl)-1H-benzimidazole
  参考文献：
  名称：

  JANSSENS, FRANS E.;KENNIS, LUDO E. J.;HENS, JOSEF F.;TORREMANS, JOSEPH L.+

  摘要：

  DOI：

文献信息

• [EN] SEROTONIN 5-HT2B RECEPTOR INHIBITORS<br/>[FR] INHIBITEURS DU RÉCEPTEUR 5-HT2B DE LA SÉROTONINE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010080357A1

  公开（公告）日：2010-07-15

  Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds.

  揭示了式I的5-HT2B受体拮抗剂。还公开了制备这些化合物的方法和使用这些化合物的方法。
• OXOPIPERAZINE DERIVATIVES
  申请人：Inthera Bioscience AG

  公开号：US20190185449A1

  公开（公告）日：2019-06-20

  The present invention relates to novel compounds of formula (I) or formula (Ia) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, and pharmaceutical compositions of these compounds which are useful for preventive and therapeutic use in human and veterinary medicine.

  本发明涉及化学式（I）或化学式（Ia）的新化合物及其药用盐、水合物、溶剂合物或立体异构体，以及这些化合物的药物组合物，可用于人类和兽医药物的预防和治疗。
• [EN] PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] MODULATEURS DE PYRROLIDINE DE L'ACTIVITE DU RECEPTEUR DES CHIMIOKINES
  申请人：MERCK & CO INC

  公开号：WO2000059503A1

  公开（公告）日：2000-10-12

  The present invention is directed to pyrrolidine compounds of formula (I) (wherein R?1, R2, R3, R4, R5, R6¿ and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.

  本发明涉及式(I)的吡咯烷化合物（其中R1，R2，R3，R4，R5，R6和n的定义如下），它们可用作趋化因子受体活性调节剂。特别地，这些化合物可用作趋化因子受体CCR-5和/或CCR-3的调节剂。
• Pyrimidinonesulfamoylureas`
  申请人：——

  公开号：US20030171368A1

  公开（公告）日：2003-09-11

  The disclosure is directed to compounds of the formula (I) 1 wherein the radicals have the meanings described in the disclosure, to the preparation of the compounds and to the use of the compounds to find the integrin receptors.

  本公开涉及式(I)1的化合物，其中基团具有公开说明中所描述的含义，以及制备该化合物和使用该化合物寻找整合素受体的方法。
• Serotonin 5-HT2B Receptor Inhibitors
  申请人：Cogan Derek

  公开号：US20110269742A1

  公开（公告）日：2011-11-03

  Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds.

  本发明涉及公开了化学式I的血清素5-HT2B受体抑制剂。还公开了制备这些化合物的方法和使用这些化合物的方法。